Glaukos uraikan target penjualan bersih 2026 sebesar $680 juta-$700 juta seiring iDose TR yang diproyeksikan mencapai $275 juta-$280 juta (NYSE:GKOS)
· seekingalpha.com
Panggilan laba Kuartal 2 2026 Glaukos (GKOS): rekor penjualan, kenaikan panduan 2026, pertumbuhan iDose TR/Epioxa, prospek margin & risiko.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...